Reblozyl luspatercept

Drug Class

Erythroid maturation agent

Mechanism

Binds specific TGF-beta superfamily ligands, reducing SMAD2/3 signaling to promote late-stage erythroid differentiation and maturation.

Approved Indication

Treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions; or anemia failing or naive to an erythropoiesis-stimulating agent (ESA) in very low- to intermediate-risk myelodysplastic syndromes (MDS).

What This Means For Patients

Reblozyl (luspatercept) is a therapeutic fusion protein that aids in red blood cell development to reduce transfusion needs for patients with beta thalassemia and myelodysplastic syndromes. It is clinically accessible in Boao Lecheng under Hainan's special-import pilot-zone policy.

Regulatory Approvals

• FDA — approved (2019) — label
• EMA — approved (2020) — source
• NMPA — approved (2022) — source

Pivotal Clinical Evidence

• COMMANDS — Platzbecker et al., Lancet 2023 (NCT03682536) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761136s009lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
• https://www.nmpa.gov.cn/